Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Nov;8(11):E1520-E1524.
doi: 10.21037/jtd.2016.11.91.

A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting

Cesare Gridelli  1 , Tania Losanno  2
Affiliations
Comment

A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting

Cesare Gridelli et al. J Thorac Dis. 2016 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr. C Gridelli received honoraria as advisory board member and speaker bureau member for Eli Lilly, Astra Zeneca and Roche. T Losanno has no conflicts of interest to declare.

Comment on

References

    1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. 10.1056/NEJMoa040938 - DOI - PubMed
    1. National Comprehensive Cancer Network. NCCN Guidelines version 3.2017. Available online: http://www.nccn.org/professionals/physician_gls/pdf/nsclc.pdf
    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57. 10.1056/NEJMoa0810699 - DOI - PubMed
    1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8. 10.1056/NEJMoa0909530 - DOI - PubMed
    1. Douillard JY, Ostoros G, Cobo M, et al. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br J Cancer 2014;110:55-62. 10.1038/bjc.2013.721 - DOI - PMC - PubMed